Aniridia is a devastating ocular disease requiring intensive eye care, social and community support from birth and throughout an individual’s lifetime.

Recent News

© 2019 Aniridia-net.eu – University of Cologne – Webdesign by Effect Group Ltd.

Novel dissertation by Erlend S. Landsend exploring visual disabling manifestations in congenital aniridia.

Patients with congenital aniridia demonstrate altered tear osmolarity and inflammatory profile, as well as ocular surface damage that correlates with the development of meibomian gland dysfunction, keratopathy and dry eye disease. Patients also show foveal hypoplasia with diminished fundus autofluorescence intensity. These are the main conclusions of an aniridia-focused investigative work titled “Congenital Aniridia: Exploring Visual Disabling Manifestations in the Ocular Surface and Ocular Fundus through Clinical and Translational Approaches” that has involved the examination of up to 35 subjects with congenital aniridia, as well as an equivalent number of healthy subjects. This research was successfully defended as a PhD Thesis by its principal author, Dr. Erlend Sommer Landsend, MD, from Oslo, Norway, which took place on 13th February 2020 in Oslo. These high-quality investigations were directed by Prof. Tor Paaske Utheim, from the University of Oslo in Norway as main tutor, and co-supervised by Prof. Neil Lagali, from the University of Linkoping of Sweden, Prof. Rigmor Baraas from the University of South-Eastern Norway, and Prof. Ragnheiður Bragadòttir from the University of Oslo in Norway. The opponent in the public defence act was Prof. Peter Netland from the University of Virginia, an international expert on aniridia and glaucoma. These novel findings will contribute to the physiological understanding of the disease facilitating diagnosis, treatment decisions as well as future research in patients suffering from aniridia. Find all the technical details of this dissertation in the three research articles that it comprises (Landsend et al. Bjophthalmol, 2019; Landsend et al. Invest Ophthalmol Vis Sci, 2018; Landsend et al. Invest Ophthalmol Vis Sci, 2018, see Publications & more section.

Dr. Erlend Sommer Landsend (third left) together with his supervisors and the adjudication committee. From left: Prof. Rigmor Baraas, Prof. Neil Lagali, Dr. Erlend Sommer Landsend, Prof. Tor Utheim, Prof. Ragnheiour Bragadòttir, Ass. Prof. Tora Sund Morken, Prof. Peter Netland, Prof. Thond Buanes, and Prof. Em. Terje Lomo (Chair of the defence).
No Comments

Post A Comment